A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2008-09-01

Target enrollment:

Participant gender:

20 eligible subjects will be enrolled into the treatment phase of the trial.

Phase 1

Mannkind Corporation